Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on novel cancer therapies that target nuclear export dysregulation. Its lead product, XPOVIO (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor approved in the U.S. in multiple oncology indications and in various indications across more than 50 ex-U.S. territories and countries, according to company statements.
This news page aggregates company-issued updates and market disclosures related to Karyopharm. Readers can follow announcements on XPOVIO commercial performance, such as reported U.S. net product revenue and trends in license and royalty revenue from international partners, as described in the company’s earnings releases. The feed also covers progress in Karyopharm’s clinical pipeline, including multiple myeloma, endometrial cancer, myelofibrosis and diffuse large B-cell lymphoma (DLBCL).
Recent news has highlighted key milestones in late-stage development, including completion of enrollment in the Phase 3 SENTRY trial (XPORT-MF-034) in myelofibrosis and ongoing enrollment in the global Phase 3 XPORT-EC-042 trial in TP53 wild-type advanced or recurrent endometrial cancer. Company releases also describe Phase 2 data in heavily pretreated myelofibrosis patients and the design of additional studies such as SENTRY-2 and XPORT-MM-031 in multiple myeloma.
In addition to clinical and commercial updates, Karyopharm’s news includes financial results, preliminary revenue disclosures, strategic financing transactions involving term loans and convertible notes, and inducement equity awards granted under its inducement stock incentive plan. Investors and observers can use this page to review the company’s own descriptions of its operational progress, financing activities and anticipated clinical catalysts as reported in press releases and referenced in SEC filings.
Karyopharm Therapeutics (Nasdaq: KPTI) announced a positive opinion from the European Medicines Agency's CHMP recommending the approval of NEXPOVIO® (selinexor) for adults with multiple myeloma who have undergone 1-3 prior therapies. This recommendation is a crucial step towards receiving marketing authorization from the European Commission, expected in about 60 days. Supported by the Phase 3 BOSTON study, the treatment demonstrated significant improvements in progression-free survival and overall response rate. The collaboration with Menarini will aid in commercialization across Europe.
Karyopharm Therapeutics (Nasdaq: KPTI) and Menarini Group announced a positive recommendation from the EMA’s CHMP for NEXPOVIO® (selinexor) in combination with bortezomib and low-dose dexamethasone for treating adult multiple myeloma patients with one to three prior therapies. This recommendation precedes a final decision from the European Commission, expected in about 60 days. The application is supported by Phase 3 BOSTON study data, showing significant improvements in progression-free survival and overall response rates compared to standard therapy.
Karyopharm Therapeutics (NASDAQ: KPTI) announced that initial data from a Phase 1 study of selinexor combined with ruxolitinib in treatment-naïve myelofibrosis patients will be presented at the EHA 2022 Congress in Vienna and the ASCO Annual Meeting. The need for innovative treatments for myelofibrosis is emphasized as current therapies are limited to JAK inhibitors. The presentation highlights the potential of selinexor in improving patient outcomes, including spleen size reduction and quality of life. Further data updates will follow at both conferences.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced participation in the 2022 RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 4:35 p.m. ET in New York, NY. The company's senior management will engage in a fireside chat, with a live webcast available in the Investor section of their website. Karyopharm is noted for pioneering novel cancer therapies, including their lead SINE compound, XPOVIO®, which is approved in several oncology indications. The event will be available for replay for 90 days.
Karyopharm Therapeutics reported a strong first quarter for 2022 with net revenues of $47.7 million, a growth of 105% compared to Q1 2021. The net product revenue from XPOVIO reached $28.3 million, marking a 30% year-over-year increase. The company announced promising clinical results for selinexor in endometrial cancer and myelofibrosis, with plans for a registration-enabling study in the second half of 2022. However, Karyopharm reported a net loss of $41.4 million, but this was an improvement from a loss of $57.4 million in the prior year.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the granting of stock options and restricted stock units (RSUs) to newly-hired employees and Dr. Reshma Rangwala, the new Chief Medical Officer. Dr. Rangwala received options for 100,000 shares and 65,000 RSUs, while twelve other employees received a total of 36,800 stock options and 25,400 RSUs. All awards are part of the 2022 Inducement Stock Incentive Plan and have a four-year vesting schedule. Each stock option has an exercise price of $6.10, based on the closing stock price on April 29, 2022.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has announced that it will report its first quarter 2022 financial results on May 5, 2022, at 8:30 a.m. ET. The company's management will host a conference call to discuss the results and company updates. Karyopharm is recognized for its pioneering work in cancer therapies, particularly with its lead compound, XPOVIO® (selinexor), which is approved in the U.S. for multiple oncology indications. The company continues to expand its presence in international markets, including Europe and Asia.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has announced that four abstracts related to selinexor clinical research will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 3-7, 2022. Key presentations include an oral study on selinexor's effects in endometrial cancer and a poster discussion on its combination with ruxolitinib for myelofibrosis. This highlights Karyopharm's commitment to innovative treatments in oncology, focusing on cancers with significant unmet needs.
Karyopharm Therapeutics (Nasdaq: KPTI) announced participation in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference, scheduled for April 14, 2022, at 9:30 a.m. ET. The virtual conference will include a live webcast accessible on Karyopharm's investor website, which will be available for replay for 90 days post-event. Karyopharm is recognized for its pioneering work in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, with its lead product, XPOVIO® (selinexor), approved in multiple cancer indications.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the approval of stock options for 58,600 shares and 36,900 restricted stock units (RSUs) to six newly-hired employees. These equity awards, granted on March 31, 2022, are part of the 2022 Inducement Stock Incentive Plan. Each stock option has an exercise price of $7.37 per share and will vest over four years. RSUs will also vest over four years, with a 25% vesting at each anniversary. These awards serve as inducements for new employees in line with Nasdaq Listing Rule 5635(c)(4).